mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma

SIMPLE SUMMARY: From a screen for metabolic inhibition by a panel of approved anticancer drugs and combining the lead compound with a mammalian target of rapamycin complex 1 (mTORC1) inhibitor, we demonstrated that the combination of ponatinib and sirolimus leads to synergistic tumor growth inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazim, Uddin Md., Bishayee, Kausik, Kang, Jieun, Yoo, Dongkwan, Huh, Sung-Oh, Sadra, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179535/
https://www.ncbi.nlm.nih.gov/pubmed/35681744
http://dx.doi.org/10.3390/cancers14112766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179535/
https://www.ncbi.nlm.nih.gov/pubmed/35681744
http://dx.doi.org/10.3390/cancers14112766

Ejemplares similares